HK1085736A1 - P2x7 receptor antagonists and their use p2x7 - Google Patents

P2x7 receptor antagonists and their use p2x7

Info

Publication number
HK1085736A1
HK1085736A1 HK06105844.1A HK06105844A HK1085736A1 HK 1085736 A1 HK1085736 A1 HK 1085736A1 HK 06105844 A HK06105844 A HK 06105844A HK 1085736 A1 HK1085736 A1 HK 1085736A1
Authority
HK
Hong Kong
Prior art keywords
receptor antagonists
antagonists
receptor
Prior art date
Application number
HK06105844.1A
Other languages
English (en)
Inventor
Richard Evans
Christine Eyssade
Rhonan Ford
Barrie Martin
Toby Thompson
Paul Willis
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38812906&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1085736(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of HK1085736A1 publication Critical patent/HK1085736A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Quinoline Compounds (AREA)
HK06105844.1A 2003-06-02 2006-05-20 P2x7 receptor antagonists and their use p2x7 HK1085736A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0312609.1A GB0312609D0 (en) 2003-06-02 2003-06-02 Novel compounds
SE0301700A SE0301700D0 (sv) 2003-06-02 2003-06-10 Novel compounds
PCT/SE2004/000836 WO2004106305A1 (en) 2003-06-02 2004-06-01 New p2x7 receptor antagonists and their use

Publications (1)

Publication Number Publication Date
HK1085736A1 true HK1085736A1 (en) 2006-09-01

Family

ID=38812906

Family Applications (1)

Application Number Title Priority Date Filing Date
HK06105844.1A HK1085736A1 (en) 2003-06-02 2006-05-20 P2x7 receptor antagonists and their use p2x7

Country Status (26)

Country Link
US (2) US7408065B2 (de)
EP (1) EP1633717B1 (de)
JP (1) JP4682128B2 (de)
KR (1) KR101244971B1 (de)
CN (1) CN1832925B (de)
AR (1) AR045691A1 (de)
AT (1) ATE446953T1 (de)
AU (1) AU2004242626B2 (de)
BR (1) BRPI0410933A (de)
CA (1) CA2526884C (de)
CO (1) CO5700720A2 (de)
DE (1) DE602004023840D1 (de)
ES (1) ES2333721T3 (de)
GB (1) GB0312609D0 (de)
HK (1) HK1085736A1 (de)
IS (1) IS8190A (de)
MX (1) MXPA05012883A (de)
NO (1) NO20060001L (de)
RU (1) RU2347778C2 (de)
SA (1) SA04250155B1 (de)
SE (1) SE0301700D0 (de)
TW (1) TW200508214A (de)
UA (1) UA83659C2 (de)
UY (1) UY28342A1 (de)
WO (1) WO2004106305A1 (de)
ZA (1) ZA200509706B (de)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0312609D0 (en) 2003-06-02 2003-07-09 Astrazeneca Ab Novel compounds
US7141596B2 (en) 2003-10-08 2006-11-28 Incyte Corporation Inhibitors of proteins that bind phosphorylated molecules
JP2008513426A (ja) * 2004-09-20 2008-05-01 バイオリポックス エービー 炎症の治療に有用なピラゾール化合物
US20090227555A2 (en) * 2005-01-06 2009-09-10 Astrazeneca Ab Novel Pyridine Compounds
US7297700B2 (en) * 2005-03-24 2007-11-20 Renovis, Inc. Bicycloheteroaryl compounds as P2X7 modulators and uses thereof
WO2006110516A1 (en) * 2005-04-11 2006-10-19 Abbott Laboratories Acylhydrazide p2x7 antagonists and uses thereof
WO2007008140A1 (en) * 2005-07-13 2007-01-18 Astrazeneca Ab New pyridine analogues
MX2008001612A (es) * 2005-08-01 2008-04-04 Phenomix Corp Metodos para preparar acidos boronicos heterociclicos y derivados de los mismos.
US7547782B2 (en) 2005-09-30 2009-06-16 Bristol-Myers Squibb Company Met kinase inhibitors
TW200800911A (en) * 2005-10-20 2008-01-01 Biolipox Ab Pyrazoles useful in the treatment of inflammation
TW200732320A (en) * 2005-10-31 2007-09-01 Biolipox Ab Pyrazoles useful in the treatment of inflammation
WO2007051982A1 (en) * 2005-10-31 2007-05-10 Biolipox Ab Triazole compounds as lipoxygenase inhibitors
JP2009513692A (ja) * 2005-11-01 2009-04-02 バイオリポックス エービー 炎症の治療に有用なピラゾール化合物
US8007849B2 (en) * 2005-12-14 2011-08-30 International Flavors & Fragrances Inc. Unsaturated cyclic and acyclic carbamates exhibiting taste and flavor enhancement effect in flavor compositions
MX2008011919A (es) * 2006-03-16 2008-11-28 Renovis Inc Compuestos de bicicloheteroarilo como moduladores de p2x7 y usos de los mismos.
EP1996585A4 (de) * 2006-03-16 2010-03-10 Renovis Inc Bicycloheteroaryl-verbindungen als px27-modulatoren und ihre verwendungen
TWI464148B (zh) 2006-03-16 2014-12-11 Evotec Us Inc 作為ｐ２ｘ7調節劑之雙環雜芳基化合物與其用途
WO2007109172A2 (en) * 2006-03-16 2007-09-27 Renovis, Inc. Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
WO2008013494A1 (en) * 2006-07-27 2008-01-31 Astrazeneca Ab Quinoline derivatives as p2x7 receptor antagonist and their use in the treatment of rheumatoid arthritis, osteoarthritis, copd and ibd
AU2007302061B2 (en) * 2006-09-28 2012-01-19 F. Hoffmann-La Roche Ag Quinoline derivatives with 5-HT-binding properties
EA201300152A1 (ru) 2006-11-27 2013-07-30 Х. Лундбекк А/С Гетероариламидные производные
BRPI0720078A2 (pt) * 2006-12-07 2013-12-24 Hoffmann La Roche 2-aminoquinolinas como antagonistas de receptores de 5-ht(5a)
AR065806A1 (es) * 2007-03-22 2009-07-01 Astrazeneca Ab Derivados de quinolina, procesos para su preparacion, composiciones farmaceuticas que los contienen y usos para el tratamiento de la artritis reumatoidea.
WO2008124153A1 (en) 2007-04-10 2008-10-16 H. Lundbeck A/S Heteroaryl amide analogues as p2x7 antagonists
US8106073B2 (en) * 2007-11-30 2012-01-31 Astrazeneca Ab Quinoline derivatives 057
WO2009108551A2 (en) * 2008-02-25 2009-09-03 H. Lundbeck A/S Heteroaryl amide analogues
WO2009109491A1 (en) 2008-03-07 2009-09-11 F. Hoffmann-La Roche Ag 2-aminoquinoline derivatives
CA2719745C (en) 2008-03-25 2016-07-05 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
CA2722035C (en) * 2008-04-22 2016-10-11 Janssen Pharmaceutica Nv Quinoline or isoquinoline substituted p2x7 antagonists
AU2010237302A1 (en) 2009-04-14 2011-12-01 Affectis Pharmaceuticals Ag Novel P2X7R antagonists and their use
MX2011012712A (es) * 2009-05-29 2012-01-30 Raqualia Pharma Inc Derivados de carboxamida sustituidos con arilo como bloqueadores del canal de calcio o sodio.
JP2013526496A (ja) 2010-05-14 2013-06-24 アフェクティス ファーマシューティカルズ アーゲー Ｐ２ｘ７ｒ拮抗剤の新規調製方法
WO2012110190A1 (en) 2011-02-17 2012-08-23 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
WO2012163456A1 (en) 2011-05-27 2012-12-06 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
WO2012163792A1 (en) 2011-05-27 2012-12-06 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
AU2012288511A1 (en) 2011-07-22 2014-03-13 Actelion Pharmaceuticals Ltd Heterocyclic amide derivatives as P2X7 receptor antagonists
US9409917B2 (en) 2012-01-20 2016-08-09 Actelion Pharmaceuticals Ltd. Heterocyclic amide derivatives as P2X7 receptor antagonists
MA38192B1 (fr) 2012-12-12 2017-11-30 Actelion Pharmaceuticals Ltd Dérivés d'indole carboxamide utilisés en tant qu'antagonistes du récepteur p2x7
AR094053A1 (es) 2012-12-18 2015-07-08 Actelion Pharmaceuticals Ltd Derivados de indol carboxamida como antagonistas del receptor p2x₇
CN104918617B (zh) 2013-01-22 2017-05-10 埃科特莱茵药品有限公司 作为p2x7受体拮抗剂的杂环酰胺衍生物
ES2616883T3 (es) 2013-01-22 2017-06-14 Actelion Pharmaceuticals Ltd. Derivados amida heterocíclicos como antagonistas del receptor P2X7
US9604982B2 (en) 2013-03-14 2017-03-28 Janssen Pharmaceutica Nv P2X7 modulators
JO3509B1 (ar) 2013-03-14 2020-07-05 Janssen Pharmaceutica Nv معدلات p2x7
WO2014152537A1 (en) 2013-03-14 2014-09-25 Janssen Pharmaceutica Nv P2x7 modulators
JO3773B1 (ar) 2013-03-14 2021-01-31 Janssen Pharmaceutica Nv معدلات p2x7
EP3152192A1 (de) * 2014-06-05 2017-04-12 Merck Patent GmbH Neuartige chinolinderivate und deren verwendung bei neurodegenerativen erkrankungen
JP6592510B2 (ja) 2014-09-12 2019-10-16 ヤンセン ファーマシューティカ エヌ．ベー． Ｐ２ｘ７調節因子
CN106084068B (zh) * 2016-06-16 2019-07-16 郑州大学第一附属医院 一组肠菌素-抗生素衍生物及其应用
MY195013A (en) * 2017-03-13 2022-12-31 Raqualia Pharma Inc Tetrahydroquinoline derivatives as p2x7 receptor antagonists
EP3398941A1 (de) * 2017-05-03 2018-11-07 AXXAM S.p.A. Heterozyklische p2x7-antagonisten
CA3111309A1 (en) 2018-09-28 2020-04-02 Janssen Pharmaceutica Nv Monoacylglycerol lipase modulators
JOP20210058A1 (ar) 2018-09-28 2021-03-24 Janssen Pharmaceutica Nv مُعدلات ليباز أُحادِيُّ الجلِيسِريد
EP4038070A1 (de) 2019-09-30 2022-08-10 Janssen Pharmaceutica NV Radiomarkierte mgl-pet-liganden
CA3176946A1 (en) 2020-03-26 2021-09-30 Janssen Pharmaceutica Nv Monoacylglycerol lipase modulators

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3352912A (en) 1963-07-24 1967-11-14 Du Pont Adamantanes and tricyclo[4. 3. 1. 1 3.8] undecanes
US3471491A (en) 1967-08-28 1969-10-07 Squibb & Sons Inc Adamantyl-s-triazines
US3464998A (en) 1968-03-04 1969-09-02 Searle & Co Adamantyl esters and amides of pyridinecarboxylic acids
GB1274652A (en) 1968-08-27 1972-05-17 Lilly Industries Ltd Adamantanyl-alkylamine derivatives and their preparation
US3741491A (en) * 1971-11-29 1973-06-26 Leesona Corp Apparatus for winding yarn
IL53441A0 (en) 1977-11-22 1978-01-31 Teva Pharma Methyladamantyl hydrazines their preparation and pharmaceutical compositions containing them
US4751292A (en) 1985-07-02 1988-06-14 The Plant Cell Research Institute, Inc. Adamantyl purines
DE69216873T2 (de) 1991-02-21 1997-08-21 Sankyo Co Benzolderivate zum Fördern der Produktion des Nervenwachstumsfaktors
ES2152989T3 (es) 1993-08-10 2001-02-16 Black James Foundation Ligandos para los receptores de gastrina y cck.
EP0804419B1 (de) 1994-05-27 2003-08-06 SmithKline Beecham Farmaceutici S.p.A. Chinolinderivate als tachykinin nk3 rezeptor antagonisten
AR004735A1 (es) 1995-11-24 1999-03-10 Smithkline Beecham Spa Quinoleina 4-amido sustituida, un procedimiento para su preparacion, una composicion farmaceutica que los contiene y el uso de los mismos para lapreparacion de un medicamento.
TR199802385T2 (xx) 1996-05-20 1999-04-21 Darwin Discovery Limited TNF inhibit�rleri ve FDE-IV inhibit�rleri olarak kinolin karboksamidler.
FR2761358B1 (fr) 1997-03-27 1999-05-07 Adir Nouveaux composes de n-aryl piperidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
JP2001524468A (ja) 1997-11-21 2001-12-04 エヌピーエス ファーマシューティカルズ インコーポレーテッド 中枢神経系疾患を治療するための代謝調節型グルタミン酸受容体アンタゴニスト
SE9704544D0 (sv) 1997-12-05 1997-12-05 Astra Pharma Prod Novel compounds
SE9704545D0 (sv) 1997-12-05 1997-12-05 Astra Pharma Prod Novel compounds
KR100710091B1 (ko) 1999-04-09 2007-04-25 아스트라제네카 아베 아다만탄 유도체
CN1361768A (zh) 1999-06-02 2002-07-31 Nps药物有限公司 代谢移变的谷氨酸盐受体拮抗剂和它们治疗中枢神经系统疾病的用途
CA2389681C (en) * 1999-11-26 2010-11-02 Shionogi & Co., Ltd. Npy y5 antagonist
GB0013737D0 (en) 2000-06-07 2000-07-26 Astrazeneca Ab Novel compounds
SK286759B6 (sk) 2001-07-02 2009-05-07 N.V. Organon Tetrahydrochinolínové deriváty, farmaceutický prostriedok s ich obsahom a ich použitie
WO2003042190A1 (en) 2001-11-12 2003-05-22 Pfizer Products Inc. N-alkyl-adamantyl derivatives as p2x7-receptor antagonists
SE0103836D0 (sv) 2001-11-16 2001-11-16 Astrazeneca Ab Novel compounds
JP2005519876A (ja) 2001-11-27 2005-07-07 メルク　エンド　カムパニー　インコーポレーテッド ２−アミノキノリン化合物
SE0200920D0 (sv) * 2002-03-25 2002-03-25 Astrazeneca Ab Novel compounds
GB0312609D0 (en) 2003-06-02 2003-07-09 Astrazeneca Ab Novel compounds
SE0302139D0 (sv) 2003-07-28 2003-07-28 Astrazeneca Ab Novel compounds
SE0402925D0 (sv) 2004-11-30 2004-11-30 Astrazeneca Ab Novel Compounds

Also Published As

Publication number Publication date
CA2526884A1 (en) 2004-12-09
NO20060001L (no) 2006-03-02
CN1832925A (zh) 2006-09-13
KR101244971B1 (ko) 2013-03-18
UA83659C2 (ru) 2008-08-11
EP1633717B1 (de) 2009-10-28
ES2333721T3 (es) 2010-02-26
US7408065B2 (en) 2008-08-05
EP1633717A1 (de) 2006-03-15
GB0312609D0 (en) 2003-07-09
WO2004106305A1 (en) 2004-12-09
CA2526884C (en) 2012-10-16
SE0301700D0 (sv) 2003-06-10
RU2005136130A (ru) 2006-06-27
TW200508214A (en) 2005-03-01
AU2004242626A1 (en) 2004-12-09
AR045691A1 (es) 2005-11-09
BRPI0410933A (pt) 2006-06-27
MXPA05012883A (es) 2006-02-22
ATE446953T1 (de) 2009-11-15
ZA200509706B (en) 2006-12-27
JP4682128B2 (ja) 2011-05-11
SA04250155B1 (ar) 2008-11-15
IS8190A (is) 2005-12-21
RU2347778C2 (ru) 2009-02-27
DE602004023840D1 (de) 2009-12-10
KR20060015741A (ko) 2006-02-20
UY28342A1 (es) 2004-12-31
JP2006526617A (ja) 2006-11-24
CN1832925B (zh) 2010-05-05
US20090143354A1 (en) 2009-06-04
AU2004242626B2 (en) 2008-03-13
US20060293337A1 (en) 2006-12-28
CO5700720A2 (es) 2006-11-30

Similar Documents

Publication Publication Date Title
HK1085736A1 (en) P2x7 receptor antagonists and their use p2x7
IL162825A0 (en) Fluoro substituted cycloalkanoindoles and their use asprotaglandin d2 receptor antagonists
IL183541A0 (en) Toll like receptor 3 antagonists, methods and uses
IL161329A0 (en) Benzamide and heteroarylamide as p2x7 receptor antagonists
HK1090922A1 (en) Cgrp receptor antagonists cgrp
IL174538A0 (en) Thrombin receptor antagonists
EP1541585A4 (de) Cxcr4-antagonist und dessen verwendung
IL176350A0 (en) Crf receptor antagonists and methods relating thereto
AU2003261392A8 (en) M3muscarinic acetylcholine receptor antagonists
IL169336A0 (en) Substituted 1-piperidin-4-yl-4-pyrrolidin-3-yl-piperazine derivatives and their use as neurokinin antagonists
IL174497A0 (en) Pyridine derivatives and use thereof as urotensin ii antagonists
IL172822A0 (en) Muscarnic acetylcholine receptor antagonists
ZA200609681B (en) Pyridin-4-yl-ethynyl-imidazoles and pyrazoles as mGlu5 receptor antagonists
IL152700A0 (en) Substituted 1-aminoalkyl-lactams and their use as muscarinc receptor antagonists
EP1808446A4 (de) Il-18-rezeptor-antagonist und pharmazeutische zusammensetzung mit dem antagonisten
IL173746A0 (en) Modified il-4 mutein receptor antagonists
IL178461A0 (en) Substituted 4-alkyl -and 4-alkanoyl-piperidine derivatives and their use as neurokinin antagonists
HK1088910A1 (en) Substituted diketopiperazines and their use as oxytocyn antagonists
EP1536813A4 (de) Zusammensetzungen und verfahren mit protein-aktivierten rezeptorantagonisten
EP1796686A4 (de) Emmprin-antagonisten und ihre verwendungen
IL173265A0 (en) Imidazo-pyrimidines and triazolo-pyrimidines: benzodiazcpine receptor ligands
HK1087924A1 (en) Substituted 1-piperidin-3-yl-4-piperidin-4-yl-piperazine derivatives and their use as neurokinin antagonists
AU2002359524A8 (en) P2x7 receptor antagonists
PL370221A1 (en) 2-oxazolamines and their use as 5-ht2b receptor antagonists
EP1696949A4 (de) Vegf-rezeptor-antagonisten

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20140601